Israel-based medical device company Medasense Biometrics has obtained CE mark approval for its pain monitoring device, PMD200 to aid clinicians in providing personalised pain relief.
The new device will enable physicians to objectively examine a patient’s pain in critical care situations, where patients are unable to communicate the condition, thereby paving the way for a better pain management.
The PMD200 has been developed as a pain monitoring device based on the patented NOL technology that quantifies patients’ physiological response to pain.
